Review article

Plasma cell and B cell-targeted treatments for use in advanced multiple sclerosis

David Baker[a,*], Benjamin M. Jacobs[a], Sharmilee Gnanapavan[a,b], Klaus Schmierer[a,b], Gavin Giovannoni[a,b]

[a] BartsMS, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, 4 Newark Street, London E1 2AT, United Kingdom
[b] Clinical Board:Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London E1 1BB, United Kingdom

A B S T R A C T

There is increasing evidence that agents that target peripheral B cells and in some instances plasma cells can exhibit marked effects on relapsing multiple sclerosis. In addition, B cells, including plasma cells, within the central nervous system compartment are likely to play an important role in disease progression in both relapsing and progressive MS. However, current B cell-targeting antibodies may not inhibit these, because of poor penetration into the central nervous system and often oligoclonal bands of immunoglobulin persist within the cerebrospinal fluid despite immunotherapy. Through targeting B cells and plasma cells in the CNS, it may be possible to obtain additional benefit above simple peripheral depletion of B cells. As such there are a number of inhibitors of B cell function and B cell depleting agents that have been developed for myeloma and B cell leukaemia and lymphoma, which could potentially be used off-label or as an experimental treatment for advanced (progressive) MS.

1. Introduction

Although multiple sclerosis (MS) is historically considered to be a T cell-mediated autoimmune disease of the central nervous (CNS), response to therapy has demonstrated that inhibitors of B cell activity are potent inhibitors of disease (Stüve et al., 2005; reviewed in Baker et al., 2017, 2018). There is evidence that all current effective disease-modifying therapies for relapsing MS interfere with B cell function, either through depletion of B cell numbers or inhibition of effector functions, in a manner that reflects their level efficacy in relapsing MS. (Gandoglia et al., 2017; Storek et al., 2004; Dooley et al., 2016; reviewed in Baker et al., 2017; Ceronie et al., 2018). Strikingly, for any given disease-modifying agent, the degree of memory B cell inhibition correlates well with disease-modifying efficacy (Dooley et al., 2016; reviewed in Baker et al., 2017). Indeed, continuous depletion of CD20-expressing B cell subsets has led to the licencing of the first agent to treat both relapsing and primary progressive MS (Montalban et al., 2017; Hauser et al., 2017; Mulero et al., 2018).

In addition to playing a significant role in driving relapsing biology, B cells are likely to play an important role in disease progression, both in the context of relapsing and primary and secondary progressive disease, which have active components driven by the adaptive-immune response entering the CNS (Lublin, 2014) and non-active disease-associated neurodegenerative components probably driven by glial-derived immune responses that may be poorly-responsive to current disease modifying treatments (Lublin, 2014; Montalban et al., 2017; Al Salama, 2019; reviewed in Baker et al., 2018).

However, B-cell depleting monoclonal antibodies may not effectively target the B cell compartment with the CNS, as antibodies penetrate the CNS poorly (Tran et al., 2014; reviewed in Baker et al., 2018) and oligoclonal bands (OCB) often persist despite therapy (Reviewed in Pryce and Baker, 2018 and Baker et al., 2018). Therefore, by targeting B cells and plasma cells in the CNS (Fig. 1), it may be possible to obtain additional benefit above simple peripheral depletion of B cells. As such, there are a number of inhibitors of B cell function and B cell depleting agents (Fig. 1) that have been developed for myeloma and B cell leukaemia and lymphoma, which could be used off-label or as an experimental treatment for progressive MS, given that lumbar puncture and intraventricular delivery of intrathecal CD20-depleting antibodies has so far been disappointing for targeting B cell responses within the CNS (Topping et al., 2016; Komori et al., 2016; Bergman et al., 2018).

Fig. 1. Targeting domains for control B cell activity during multiple sclerosis.
Agents target plasma cells (blue) and/or B cell lineage cells (pink) cells and/or non-B cells (transparent), which are either quiescent (Dots) or dividing (Hatch). These can be targeted either in the periphery or within the periphery and central nervous system (Grey). Immunosuppressive agents that may be of value are shown, although their precise positioning is for illustrative purpose and can vary depending on the pharmacokinetic properties of the agents. Low activity against plasma cells of cladribine is based on deoxycytidine kinase levels and may not reflect events occurring in MS. BTKi Bruton's tyrosine kinase. Pi proteasome inhibitor, CY cyclophosphamide, CAR Chimeric antigen receptor. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

2. Antibodies

Monoclonal antibodies provide the most specific way of targeting particular B cell subsets. Indeed, both CD19 and CD20-specific antibodies have been found to inhibit relapsing MS (Reviewed in Baker et al., 2017 and Baker et al., 2018). However, as these markers are not expressed by plasma cells, it demonstrates that they and immunoglobulin are not essential for disease activity (Ireland et al., 2012; Baker et al., 2017). Whilst these target the mechanisms driving relapsing disease (Hauser et al., 2017; reviewed in Baker et al., 2018), CD20-depleting antibodies also can inhibit, at least active, primary progressive MS (Hawker et al., 2009; Montalban et al., 2017). This can be targeted by ocrelizumab and off-label rituximab and other antibodies in development, such as ofatumumab (Du et al., 2017; Bar-Or et al., 2018). However, the action against progressive MS may be secondary to inhibition of active disease, rather than via a direct neuroprotective effect (Hawker et al., 2009; Castillo-Trivino et al., 2013). Indeed, this may not be surprising as monoclonal antibodies fail to significantly enter the CNS (Fig. 1), CD20-depleting antibodies exhibit limited direct killing of B cells in the CNS (Topping et al., 2016; Komori et al., 2016), do not kill plasma cells (Sabatinon et al., 2019) and do not initially affect immunoglobulin levels and OCB within the cerebrospinal fluid (Castillo-Trivino et al., 2013; Sabatinon et al., 2019; Studer et al., 2014). Although, there are antibody agents that can target plasma cells, as used in myeloma such as: indatuximab (CD138-specific)-ravtansine; lorvotuzumab (CD56-specific)-mertansine, CD38 (daratu-mumab) and CD27+, memory B cells such as varlilumab (Robak & Robak 2016; Schönfeld et al., 2017; Burris et al., 2017), given the poor penetration of antibodies (99.9% excluded. Kikuchi et al., 2004; Tran et al., 2014) across the blood-brain barrier and the limited killing capacity of intrathecal-administered antibody (Topping et al., 2016; Komori et al., 2016), probably due to lack of sufficient effector mechanisms for complement fixation and/or antibody dependent cellular cytotoxicity within the CNS (Komori et al., 2016), use of antibodies does not appear to be the most optimised method to target B cells within the CNS. However, CD20-depletion could be a base on which to add neuroprotection and repair activity as the drug may have immune-reconstitution therapy potential (Baker et al., 2017). However, B cells form a central part of immunity. As such, continuous B cell depletion is associated with reductions in immunoglobulin levels and an increased risk of infection that is going to accumulate with time (Hauser et al., 2017;

Giovannoni, 2018). These risks can be significant, and is of interest that the development of ocrelizumab was terminated in other CD20-responsive autoimmunities because of infection-related fatalities adversely affecting the risk: benefit balance (Harigai et al., 2012; Emery et al., 2014). However, it may be possible to achieve benefit from pulsed therapies to avoid problems with continuous immunosuppression (Baker et al., 2017).

2.1. Small molecule immune inhibitors

B cells have a more rapid turnover than T cells and rapidly die in vitro and are susceptible to cytostatic agents that kill cells during DNA replication (Baker et al., 2017). Therefore, B cells including both regulatory and effector B cells are particularly sensitive to cytostatic agents (Minagawa et al., 1987; O'Neill et al., 1992; Baker et al., 2017). In animals this can mean that B cell therapy can have distinct and opposing activity, dependent on timing of treatments (Minagawa et al., 1987; O'Neill et al., 1992; Sefia et al., 2017). Similarly B cell immunotherapy can inhibit (Baker et al., 2017, 2018; Sabatinon et al., 2019), but in some instances augment MS, possibly due to influences on distinct B cell subsets (Kappos et al., 2014; Baker et al., 2017). Therefore, actual use will demonstrate where the therapeutic balance resides, but targeting memory B cell responses inhibits MS (Baker et al., 2017). There are a number of agents that could be used to target B cells.

Cyclophosphamide is prodrug that is metabolised to a cytostatic agent that kills rapidly dividing cells and thus can target some B cells by virtue of their activation or by because B cells exhibit a higher turnover rate compared to other cells such as T cells (Macallan et al., 2003; Macallan et al., 2005). Therefore B cells may be more sensitive to cytostatic agents, although low-dose pulsed cyclophosphamide exhibits limited effects on plasma cells and memory B cells (Fassbinder et al., 2015). However, high-dose (120 mg/kg–200 mg/kg) cyclophosphamide has been used extensively in people with progressive MS, as part of a monotherapy or as part of Haematopoeitic Stem Cell Therapy (HSCT) to induce mobilisation of CD34+ stem cells (La Mantia et al., 2007;Krishan et al., 2008; Bowen et al., 2012; Atkins et al., 2016; Brochet et al., 2017). Whilst cyclophosphamide and HSCT have exhibited marked impact on relapsing and active MS (Krishan et al., 2008; Aktins et al., 2016), people with progression have often continued to progress, although some people with advanced (progressive) MS appear to show some benefit (Bowen et al., 2012). However, people with MS

often poorly tolerate cyclophosphamide, consistent with the non-selective activity on dividing cells including hair loss and gastrointestinal problems (La mantia et al., 2007;Krishan et al., 2008). Many people continue to show some worsening and OCB have persisted (60–160 mg/kg) indicating ineffective CNS clearance of B cells within their CNS niches (Openshaw et al., 2000; Saiz et al., 2001; Carreras et al., 2003; Nash et al., 2003; Bowen et al., 2012).

Mitoxantrone is a type II topoisomerase inhibitor that disrupts DNA synthesis and repair and intercalates into DNA bases and kills dividing cells and so may target dividing B cells that are turning over (Macallan et al., 2005). Mitoxantrone depletes B cells and notably exhibits a marked impact on memory B cell in MS, consistent with its efficacy (Chan et al., 2005; Duddy et al., 2007; Baker et al., 2017). Pixantrone, a mitoxantrone analogue, is also a potent depleter of B cells (Gonsette et al., 2016). When mitoxantrone was used in combination with CD20-depletion there was marked depletion of peripheral blood B cells and also reductions, albeit to a more modest and transient level. of B cells with the cerebrospinal fluid that was associated with a positive treatment effect (Evdoshenko et al., 2013). Mitoxantrone is used for the treatment of active advanced MS (Martinelli Boneschi et al., 2013). It can show a significant but partial efficacy in reducing the risk of MS progression and the frequency of relapses in some but not all studies (Martinelli Boneschi et al., 2013; Grey Née Cotte et al., 2015). However, mitoxantrone is neurotoxic and is actively excluded from the CNS via the action of ABCG2 ATP-binding cassette transporter (Dalle et al., 2000; Cotte et al., 2009). The influence on OCB is also limited (Axelsson et al., 2013). This coupled with concerns about the risk of cardiotoxicity and therapy-related acute leukaemias, limit the value of mitoxantrone (Martinelli Boneschi et al., 2013).

Cladribine produces toxic moieties following phosphorylation of the adeonosine-analogue by deoxycytidine kinase and selectively kills, dividing and non-dividing, lymphocytes notably B lymphocytes (Giovannoni et al., 2017; Ceronie et al., 2018). Oral cladribine prodrug inhibits relapsing MS (Giovannoni et al., 2017). Likewise, parenteral, generic cladribine inhibits disease activity in relapsing and progressive disease (Giovannoni et al., 2017; Rice et al., 2000). Although there is a perceived failure in progressive MS (Beutler et al., 1996; Rice et al., 2000), the trials were too short to really demonstrate full clinical benefit and there were positive imaging and clinical effects (Rice et al., 2000) and unlike any other licensed disease modifying treatment in MS, the drug is CNS penetrant (Fig. 1) and can be active in the CNS (Kearns et al., 1994; Baker et al., 2019). Cladribine probably behaves as chemical anti-CD19 agent, with additional T cell inhibitory activity, based on the high expression of deoxycytidine kinase (DCK) in B cells, which facilitates cladribine-induced apoptosis of lymphocytes (Cocco et al., 2012; Baker et al., 2019). It is evident that DCK is expressed on early B cell lineages including immature, mature, memory B cells and plasmablasts but is down regulated in plasma cells (Cocco et al., 2012; Ceronie et al., 2018; Baker et al., 2019). However, parenteral cladribine has reduced or eliminated the occurrence of OCB in some people with MS (Sipe et al., 1994; Rejdak et al., 2018), suggesting that it can inhibit the development of plasma cells or that it blocks the factors that promote B cell niches within the CNS. Cladribine like alemtuzumab and ocrelizumab has some immune-reconstitution therapy potential, with a long-term benefit from a short course of treatment (Giovannoni et al., 2018). As such this may also provide an immunomodulatory platform on which to layer neuroprotection and repair.

Mycophenolate is a lymphocyte-selective depleting agent that is metabolised in the plasma and the liver into mycophenolic acid, which is a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH) involved in *de novo* purine biosynthesis. This pathway is essential for lymphocyte proliferation (Euqui et al., 1991). However, there is limited data concerning benefit of use in MS, but it may inhibit active disease (Michel et al., 2014; Xioa et al., 2014; Fakih et al., 2018). This agent can inhibit B cell activation and differentiation in vitro, although terminally differentiated plasma cells appear to less sensitive to

the effects of mycophenolate, possibly due to down regulation and insensitivity of the IMPDH (Karnell et al., 2011). However there does not appear to be gross changes in most B cell subsets following treatment with mycophenolic acid in humans, although in some instance plasma cells appeared to be reduced in non-MS conditions (Zhao et al., 2012; San Sequndo et al., 2012; Eickenberg et al. 2012). However the influence on B cell subsets require study and positive effects on non-active elements of progressive MS have yet to be found (Fakih et al., 2018).

2.2. B cell-selective inhibitors

Given the success of B cell depletion using CD20 monoclonal antibodies, there is significant commercial interest in developing B cell depleting agents or B cell inhibitors.

Brutons tyrosine kinase (BTK) inhibitors reversibly or irreversibly block the BTK enzyme that plays a crucial signalling role in B cell development and mutations in BTK are associated with X-linked agammaglobulinemia, where B cell fails to mature. BTK inhibitors prevent B cell activation and block downstream B cell survival pathways. There are a number of BTK inhibitors in clinical development, initially for cancer and the first study in MS has been reported to have a positive impact in active disease using evobrutinib (Montalban et al., 2019). This is a first generation BTKi that has been reported to the inhibit lesion formation and the generation of relapses in phase II trials (Montalban et al., 2019). This also inhibits macrophage function and may thus have additional activities relevant for advanced MS (Alankus et al., 2018). Some first generation agents have been approved for treating haematological malignancies and graft versus host disease, such as Ibrutinib. This is appears to be a p-glycoprotein substrate, which may limit CNS penetration (van Hoppe et al., 2018) and infections following use commonly occur (Tillman et al., 2018; Hsiehchen et al., 2018). Second generation inhibitors are been developed that have fewer side effects and greater specificity (Wu et al., 2016; Pal Singh et al., 2018). There is significant commercial interest in BTKi development and include agents such as PRM226, which is a CNS penetrant BTKi, ABBV-105 and HM71224/LY3337641 (Wu et al., 2016; Robak and Robak, 2017; Pal Singh et al., 2018). However, although caution is needed when comparing studies, the reduction in the of level formation by evobrutinib does not appear to as marked as found with CD20-depletion and this may have implications for staging within the therapeutic ladder of MS treatments (Kappos et al., 2011; Montalban et al., 2019). In addition, BTKi have been used to augment cancer therapy when used in combination with other agents (Geyer et al., 2019). It remains to be seen whether there could be benefit from being used as add-on therapy in MS. This will become clearer as more studies are undertaken and published.

2.2.1. Proteosome inhibitors

The proteasome plays a pivotal role in the control of many cell cycle-regulatory processes, including regulation of nuclear factor Kappa B activity and control of apoptosis (Schenken, 2002). Proteasome inhibitors can sensitize cells to induce apoptosis and have been used to treated multiple myeloma, using agents such as bortezomib that is partially excluded from the CNS by p-glycoprotein (Foran at al. 2016). One could use such an agent to make advantage of the finding that p-glycoprotein exclusion pump is down-regulated in MS lesions, to selectively target areas of pathology (Al-Izki et al., 2014). However, bortezomib can have undesirable side-effects such as the induction of neuropathy (Alé et al., 2014). There are second generation inhibitors such as carfilzomib and ixazomib, with more limited neuropathic effects (Karademir et al., 2018). These inhibitors target plasma cells, but also have impact on activated naïve and memory B cells and may have activity against peripheral autoimmunity (Mulder et al., 2013; Alexander et al., 2015). CNS-penetrant proteosome inhibitors such as marizomib have been generated (Di et al., 2016). It remains to be seen whether these agents will have merit in the treatment of MS and

whether they can be used long-term to treat MS, especially as protea-some activators may be neuroprotective (Schattling et al., 2019).

2.3. B cell survival factors

There are a number of B cell growth, differentiation and survival factors including interleukin 4, Interleukin 6, Interleukin 10 and Interleukin 13, lymphotoxin and tumour necrosis factor, and a number of chemokines notably B cell-attracting chemokine 1/CXCL13, which support B cell growth and survival (Housley et al., 2015). Many can be inhibited by specific monoclonal antibodies such as tocilizumab (IL-6 receptor) and siltuximab (IL-6) and others (Klimatcheva et al., 2015; Beauchemin and Carruthers, 2016). However, these will have the same CNS penetration issues as agents targeting B cell surface markers and some may have unwanted activities (Beauchemin and Carruthers, 2016; Kemanetzoglou and Andreadou, 2017). Inhibition of B cell activating factor (BAFF. TNFLS13B) and a proliferation-inducing ligand (APRIL) serves as a warning that not all B cell inhibitors are beneficial (Reviewed in Baker et al., 2017). Ataccicept is a fusion protein of the transmembrane activator and calcium modulator and cyclophilin-ligand interactor (TACI. TNFRSF13B) receptor that blocks BAFF and APRIL to deplete mature B cells and plasma cells, but not memory cells and appears to augment MS relapse (Kappos et al., 2014; Sergott et al., 2015; reviewed in Baker et al., 2017). It is therefore of interest that studies with monoclonal inhibition of BAFF using tabalumab did not inhibit lesion formation, but importantly it did appear to worsen MS (Silk & Nantz 2018). BAFF stimulates the TACI receptor, the BAFF-receptor (TNFRSF13C) expressed by most B lineage cells and the B cell maturation antigen receptor (TNFRSF17), which highly expressed by mainly be plasma cells (Mackay et al., 2003; Darce et al., 2007). APRIL stimulates TACI, expressed by memory B cells and plasma cells (www.biogps.org) and BCMA (Mackay et al., 2003; Darce et al., 2007), but interestingly inhibition of BAFF with belimumab does not appear to augment the memory B cell response (Ramsköld et al., 2019). Therefore, this not only implicates APRIL as a problematic growth factor in MS, importantly if provides yet more evidence to support the hypothesis that the memory B cells are central mediators in the pathogenesis of MS (Reviewed in Baker et al., 2017).

2.4. Tumour necrosis factor inhibitors

Tumour necrosis factor (TNF) is a plasma cell survival factor and a number of the markers involved in B cell development are members of the TNF superfamily such as CD40 and CD27, which are MS susceptibility genes (Jourdan et al., 1999; Dendrou et al., 2013; Figgett et al., 2014). Inhibitors of TNF are used to treat multiple myeloma indicating the sensitivity of B cells to these treatments. Most MS treatments are also active in other autoimmune diseases, but inhibition of TNF has been a notable exception and even appears to augment CNS demyelinating disease (Kemanetzoglou and Andreadou, 2017). Whilst it has been postulated that TNF inhibition can augment memory B cell responses and so drive relapsing MS (Baker et al., 2017), other explanations are possible (Kemanetzoglou and Andreadou, 2017). As such, because antibodies are largely excluded from the CNS, there is a possibly that there is no inhibition of TNF within the CNS and therefore no inhibition of local B cell responses occurs in MS, unlike in other TNF inhibition-sensitive peripheral autoimmunities. As such it has been shown that TNF contributes to the formation of ectopic B cell follicles and these may contribute to disease progression in MS (Paulino et al., 2018; Pryce and Baker, 2018; Baker et al., 2018). Peripheral inhibition of TNF has been shown to block B cell follicles (Cañete et al., 2009; Pryce and Baker, 2018). This would suggest benefit may be driven by targeting CNS-derived TNF (Fig. 1, Baker et al., 1994).

2.4.1. Intrathecal/ventricular TNF inhibition

There is experimental evidence the local delivery of TNF into the

CNS offers benefit over systemic delivery (Baker et al., 1994). However, given the history of anti-TNF treatment in MS, this approach will be difficult to recruit and undertake.

2.4.2. Phophosphodiesterase 4 (PDE4) inhibition

There is evidence that PDE4 inhibitors are potent TNF inhibitors and consistent with this, rolipram may even augment relapsing MS disease (Sommer et al., 1995; Bielekova et al., 2009). However, worsening was not found with Ibudilast which also did not inhibit relapsing MS (Barkhof et al., 2010). Ibudilast is a CNS-penetrant phosphodiesterase 4 and migration inhibition factor inhibitor that may have some benefit in progressive MS, in contrast to pentoxyfylline, and has slowed brain volume loss in MS (Meyers et al., 1998; Fox et al., 2018). Whether this targets intrathecal B cell responses is currently unknown.

2.4.3. Thalidomide analogues

Thalidomide is also used to treat myeloma and is a potent inhibitor of TNF, however it produces tetragenic effects. There are a number of thalidomide analogues that have fewer side effects such as: lenalidomide, pomaldomide and apremilolast. Pomalidomide is used to treat multiple myeloma (Gueneau et al., 2018). It remains to be seen whether they could target plasma cell responses in the CNS during MS.

2.5. Vaccination therapy

2.5.1. Chimeric antigen receptor T cells (CAR-T) therapy

A novel immunotherapy has emerged for cancer immunotherapy, whereby (CD8) T cells from individuals can be engineered to express cell-specific single chain variable antibody fragments that give specificity and signal T cell activation following ligation (Ruella and June, 2016). Initial targeting constructs have been designed to target all CD19 or CD20 B cells (Ruella and June, 2016; Zhang et al., 2017; Perales et al., 2018). These CART cells would have the capacity to enter the CNS to kill B cells, including the memory B cells and plasmablasts, which are the dominant B cell subsets with the CNS (Eggers et al., 2017). Tisagenlecleucel, which targets CD19 B cells has been licensed after success in cancer (Zhang et al., 2016). However, this therapy is not currently reversible and will lead to permanent depletion of all CD19 B cells, as they form and they will not directly target long-lived plasma cells that do not express CD19. These CAR-T cells will probably lead to the infection problems that have been associated with long-term B cell deletion using antibodies. The creation of more selective CAR-T and development of the technology for reversible, safer use of CART therapy would probably be ideally needed for use in MS (Duong et al., 2018; Perales et al., 2018). Recently, B cell maturation antigen (CD269) CAR-T cells have been produced for multiple myeloma, which will target B memory cells and notably plasma cells and may offer real promise for targeting pathogenic B cells with the CNS in the future (Cohen et al., 2019).

2.5.2. Epstein Barr virus vaccination to kill virally-infected B cells

Epstein Barr virus, which may be the aetiological trigger of MS, infects B cells and causes expansion of memory B cells (Burns et al., 2015; Burns et al., 2016, reviewed in Baker et al., 2018). These may presentation antigen to T cells to drive MS (Reviewed in Baker et al., 2017). This virus creates survival advantage for the B cell and therefore killing of the virus may limit B cell activity. This may be achieved using EBV-specific CD8 cytotoxic cells (Pender & Burrows, 2014). This approach is being trialled and commercially developed for MS and may offer some benefit in progressive MS (Pender et al., 2017).

3. Summary

As B cells are increasing been seen as an important pathogenic element of relapsing and progressive MS (Baker et al., 2017; Baker et al., 2018) searches for novel agents will increase. However, whilst

these may offer promise, the failure and potential worsening of some B cell inhibitory agents (Sergott et al., 2015), indicates that until appropriate trials are under taken their potential efficacy and safety cannot necessarily be predicted (Kappos et al., 2014; Sergott et al., 2015).

Funding

Disclosures of interest

References

Al-Salama, Z.T., 2019. Siponimod: first global approval. Drugs. https://doi.org/10.1007/s40265-019-01140-x. [Epub].

Alé, A., Bruna, J., Navarro, X., Udina, E., 2014. Neurotoxicity induced by antineoplastic proteasome inhibitors. Neurotoxicology 43, 28–35.

Alexander, T., Sarfert, R., Klotsche, J., Kühl, A.A., Rubbert-Roth, A., Lorenz, H.M., Rech, J., Hoyer, B.F., Cheng, Q., Waka, A., Taddeo, A., Wiesener, M., Schett, G., Burmester, G.R., Radbruch, A., Hiepe, F., Voll, R.E., 2015. The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann. Rheum. Dis. 74, 1474–1478.

Al-Izki, S., Pryce, G., Hankey, D.J., Lidster, K., von Kutzleben, S.M., Browne, L., Clutterbuck, L., Posada, C., Edith Chan, A.W., Amor, S., Perkins, V., Gerritsen, W.H., Ummenthum, K., Peferoen-Baert, R., van der Valk, P., Montoya, A., Joel, S.P., Garthwaite, J., Giovannoni, G., Selwood, D.L., Baker, D., 2014. Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis. Brain 137, 92–108.

Alankus, Y., Grenningloh, R., Haselmayer, P., Bender, A., Bruttger, J., 2018. BTK inhibition prevents inflammatory macrophage differentiation: a potential role in MS. Mult. Scler. J. 24 (S2), 264.

Atkins, H.L., Bowman, M., Allan, D., Anstee, G., Arnold, D.L., Bar-Or, A., Bence-Bruckler, I., Birch, P., Bredeson, C., Chen, J., Fergusson, D., Halpenny, M., Hamelin, L., Huebsch, L., Hutton, B., Laneuville, P., Lapierre, Y., Lee, H., Martin, L., McDiarmid, S., O'Connor, P., Ramsay, T., Sabloff, M., Walker, L., Freedman, M.S., 2016. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet 388, 576–585.

Axelsson, M., Mattsson, N., Malmeström, C., Zetterberg, H., Lycke, J., 2013. The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis. J. Neuroimmunol. 264, 100–105.

Baker, D., Butler, D., Scallon, B.J., O'Neill, J.K., Turk, J.L., Feldmann, M., 1994. Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur. J. Immunol. 24, 2040–2048.

Baker, D., Marta, M., Pryce, G., Giovannoni, G., Schmierer, K., 2017. Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis. EBioMedicine 16, 41–50.

Baker, D., Pryce, G., Amor, S., Giovannoni, G., Schmierer, K., 2018. Learning from other autoimmunities to understand targeting of B cells to control multiple sclerosis. Brain 141, 2834–2847.

Baker, D., Pryce, G., Herrod, S.S., Schmierer, K., 2019. Potential mechanisms of action related to the efficacy and safety of cladribine. Mult. Scler. Relat. Disord. 30, 176–186.

Barkhof, F., Hulst, H.E., Drulovic, J., Uitdehaag, B.M., Matsuda, K., Landin, R., MN166-001 Investigators, 2010. Ibudilast in relapsing-remitting multiple sclerosis: a neuro-protectant? Neurology 74, 1033–1040.

Bar-Or A., Grove R.A., Austin D.J., Tolson J.M., VanMeter S.A., Lewis E.W., Derosier F.J.,

Lopez M.C., Kavanagh S.T., Miller A.E., Sorensen P.S. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: tThe MIRROR study. Neurology. 2018; 90:e1805–e1814.

Bergman, J., Burman, J., Gilthorpe, J.D., Zetterberg, H., Jiltsova, E., Bergenheim, T., Svenningsson, A., 2018. Intrathecal treatment trial of rituximab in progressive MS: an open-label phase 1b study. Neurology 91, e1893–e1901.

Bielekova, B., Richert, N., Howard, T., Packer, A.N., Blevins, G., Ohayon, J., McFarland, H.F., Stürzebecher, C.S., Martin, R., 2009. Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood–brain barrier disruption in multiple sclerosis. Mult. Scler. 15, 1206–1214.

Bowen, J.D., Kraft, G.H., Wundes, A., Guan, Q., Maravilla, K.R., Gooley, T.A., McSweeney, P.A., Pavletic, S.Z., Openshaw, H., Storb, R., Wener, M., McLaughlin, B.A., Henstorf, G.R., Nash, R.A., 2012. Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results. Bone Marrow Transplant. 47, 946–951.

Brochet, B., Deloire, M.S., Perez, P., Loock, T., Baschet, L., Debouverie, M., Pittion, S., Ouallet, J.C., Clavelou, P., de Sèze, J., Collongues, N., Vermersch, P., Zéphir, H., Castelnovo, G., Labauge, P., Lebrun, C., Cohen, M., Ruet, A., PROMESS study investigators, 2017. Double-blind controlled randomized trial of cyclophosphamide versus methylprednisolone in secondary progressive multiple sclerosis. PLoS One 12, e0168834.

Beauchemin P., Carruthers R.MS arising during Tocilizumab therapy for rheumatoid arthritis. Mult. Scler.. 2016; 22:254–256.

Beutler, E., Sipe, J.C., Romine, J.S., Koziol, J.A., McMillan, R., Zyroff, J., 1996. The treatment of chronic progressive multiple sclerosis with cladribine. Proc. Natl. Acad. Sci. U S A 93, 1716–1720.

Burns, D.M., Rana, S., Martin, E., Nagra, S., Ward, J., Osman, H., Bell, A.I., Moss, P., Russell, N.H., Craddock, C.F., Fox, C.P., Chaganti, S., 2016. Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT. Bone Marrow Transplant. 51, 825–832.

Burns, D.M., Tierney, R., Shannon-Lowe, C., Croudace, J., Inman, C., Abbotts, B., Nagra, S., Fox, C.P., Chaganti, S., Craddock, C.F., Moss, P., Rickinson, A.B., Rowe, M., Bell, A.I., 2015. Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation event. Blood 126, 2665–2675.

Burris, H.A., Infante, J.R., Ansell, S.M., Nemunaitis, J.J., Weiss, G.R., Villalobos, V.M., Sikic, B.I., Taylor, M.H., Northfelt, D.W., Carson 3rd, W.E., Hawthorne, T.R., Davis, T.A., Yellin, M.J., Keler, T., Bullock, T., 2017. Safety and activity of varlilumab, a novel and first-in-class agonist anti-cd27 antibody, in patients with advanced solid tumors. J. Clin. Oncol. 35, 2028–2036.

Cañete, J.D., Celis, R., Moll, C., Izquierdo, E., Marsal, S., Sanmartí, R., Palacín, A., Lora, D., de la Cruz, J., Pablos, J.L., 2009. Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis factor α therapy in rheumatoid arthritis. Ann. Rheum. Dis. 68, 751–756.

Carreras, E., Saiz, A., Marín, P., Martínez, C., Rovira, M., Villamor, N., Aymerich, M., Lozano, M., Fernández-Avilés, F., Urbano-Izpizua, A., Montserrat, E., Graus, F., 2003. CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients. Haematologica 88, 306–314.

Castillo-Trivino, T., Braithwaite, D., Bacchetti, P., Waubant, E., 2013. Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. PLoS One 8, e66308.

Ceronie, B., Jacobs, B.M., Baker, D., Dubuisson, N., Mao, Z., Ammoscato, F., Lock, H., Longhurst, H.J., Giovannoni, G., Schmierer, K., 2018. Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells. J. Neurol. 265, 1199–1209.

Chan, A., Weilbach, F.X., Toyka, K.V., Gold, R., 2005. Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin. Exp. Immunol. 139, 152–158.

Cocco, M., Stephenson, S., Care, M.A., Newton, D., Barnes, N.A., Davison, A., Rawstron, A., Westhead, D.R., Doody, G.M., Tooze, R.M., 2012. In vitro generation of long-lived human plasma cells. J. Immunol. 189, 5773–5785.

Cohen, A.D., Garfall, A.L., Stadtmauer, E.A., Melenhorst, J.J., Lacey, S.F., Lancaster, E., Vogl, D.T., Weiss, B.M., Dengel, K., Nelson, A., Plesa, G., Chen, F., Davis, M.M., Hwang, W.T., Young, R.M., Brogdon, J.L., Isaacs, R., Pruteanu-Malinici, I., Siegel, D.L., Levine, B.L., June, C.H., Milone, M.C., 2019. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J. Clin. Invest. 21, 130 pii126397.

Cotte, S., von Ahsen, N., Kruse, N., Huber, B., Winkelmann, A., Zettl, U.K., Starck, M., König, N., Tellez, N., Dörr, J., Paul, F., Zipp, F., Lühder, F., Koepsell, H., Pannek, H., Montalban, X., Gold, R., Chan, A., 2009. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantroneresponse in multiple sclerosis. Brain 132, 2517–2530.

Dalle, J.H., Lambilliotte, A., Defachelles, A.S., Mazingue, F., Nelken, B., 2000. Intrathecal mitozantrone has to be prohibited. Leukemia 14, 2323–2324.

Darce, J.R., Arendt, B.K., Wu, X., Jelinek, D.F., 2007. Regulated expression of BAFF-binding receptors during human B cell development. J. Immmunol. 179, 7276–7286.

Dendrou, C.A., Bell, J.I., Fugger, L., 2013. A clinical conundrum: the detrimental effect of TNF antagonists in multiple sclerosis. Pharmacogenomics 14, 1397–1404.

Di, K., Lloyd, G.K., Abraham, V., MacLaren, A., Burrows, F.J., Desjardins, A., Trikha, M., Bota, D.A., 2016. Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier. Neuro Oncol. 18, 840–848.

Dooley, J., Pauwels, I., Franckaert, D., Smets, I., Garcia-Perez, J.E., Hilven, K., Danso-Abeam, D., Terbeek, J., Nguyen, A.T., De Muynck, L., Decallonne, B., Dubois, B., Liston, A., Goris, A., 2016. Immunologic profiles of multiple sclerosis treatments reveal shared early B cell alterations. Neurol. Neuroimmunol. Neuroinflamm. 3, e240.

Du, F.H., Mills, E.A., Mao-Draayer, Y., 2017. Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment. Auto Immun. Highlights 8, 12.

Duddy, M., Niino, M., Adatia, F., 2007. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J. Immunol. 178, 6092–6099.

Duong, M.T., Collinson-Pautz, M.R., Morschl, E., Lu, A., Szymanski, S.P., Zhang, M., Brandt, M.E., Chang, W.C., Sharp, K.L., Toler, S.M., Slawin, K.M., Foster, A.E., Spencer, D.M., Bayle, J.H., 2018. Two-dimensional regulation of CAR-T cell therapy with orthogonal switches. Mol. Ther. Oncolytics 12, 124–137.

Eggers, E.L., Michel, B.A., Wu, H., Wang, S.Z., Bevan, C.J., Abounasr, A., Pierson, N.S., Bischof, A., Kazer, M., Leitner, E., Greenfield, A.L., Demuth, S., Wilson, M.R., Henry, R.G., Cree, B.A., Hauser, S.L., von Büdingen, H.C., 2017. Clonal relationships of CSF B cells in treatment-naive multiple sclerosis patients. JCI Insight 2, 92724 pii.

Eickenberg, S., Mickholz, E., Jung, E., Nofer, J.R., Pavenstadt, H.J., Jacob, A.M., 2012. Mycophenolic acid counteracts B cell proliferation and plasmablast formation in patients with systemic lupus erythematosus. Arth. Res. Ther. 14, R110.

Emery, P., Rigby, W., Tak, P.P., Dörner, T., Olech, E., Martin, C., Millar, L., Travers, H., Fisheleva, E., 2014. Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program. PLoS One 9, e87379.

Evdoshenko, E., Maslyanskiy, A., Lapin, S., Zaslavsky, L., Dobson, R., Totolian, A., Skoromets, A., Bar-Or, A., 2013. Dynamics of B-cell populations in CSF and blood in patients treated with a combination of rituximab and mitoxantrone. ISRN Neurol. 2013, 748127.

Eugui, E.M., Almquist, S.J., Muller, C.D., Allison, A.C., 1991. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand. J. Immunol. 33, 161–173.

Fakih, R., Matiello, M., Chitnis, T., Stankiewicz, J.M., 2018. Efficacy and safety of mycophenolate mofetil in progressive multiple sclerosis patients. J. Neurol. 265, 2688–2694.

Fassbinder, T., Saunders, U., Mickholz, E., Jung, E., Becker, H., Schlüter, B., Jacobi, A.M., 2015. Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus. Arthritis Res. Ther. 17, 92.

Figgett, W.A., Vincent, F.B., Saulep-Easton, D., Mackay, F., 2014. Roles of ligands from the TNF superfamily in B cell development, function, and regulation. Semin. Immunol. 26, 191–202.

Foran, E., Kwon, D.Y., Nofziger, J.H., Arnold, E.S., Hall, M.D., Fischbeck, K.H., Burnett, B.G., 2016. CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy. Neurobiol. Dis. 88, 118–124.

Fox, R.J., Coffey, C.S., Conwit, R., Cudkowicz, M.E., Gleason, T., Goodman, A., Klawiter, E.C., Matsuda, K., McGovern, M., Naismith, R.T., Ashokkumar, A., Barnes, J., Ecklund, D., Klingner, E., Koepp, M., Long, J.D., Natarajan, S., Thornell, B., Yankey, J., Bermel, R.A., Debbins, J.P., Huang, X., Jagodnik, P., Lowe, M.J., Nakamura, K., Narayanan, S., Sakaie, K.E., Thoomukuntla, B., Zhou, X., Krieger, S., Alvarez, E., Apperson, M., Bashir, K., Cohen, B.A., Coyle, P.K., Delgado, S., Dewitt, L.D., Flores, A., Giesser, B.S., Goldman, M.D., Jubelt, B., Lava, N., Lynch, S.G., Moses, H., Ontaneda, D., Perumal, J.S., Racke, M., Repovic, P., Riley, C.S., Severson, C., Shinnar, S., Suski, V., Weinstock-Guttman, B., Yadav, V., Zabeti, A., NN102/SPRINT-MS Trial Investigators, 2018. Phase 2 trial of ibudilast in progressive multiple sclerosis. N. Engl. J. Med. 379, 846–855.

Gandoglia, I., Ivaldi, F., Laroni, A., Benvenuto, F., Solaro, C., Mancardi, G., Kerlero de Rosbo, N., Uccelli, A., 2017. Teriflunomide treatment reduces B cells in patients with MS. Neurol. Neuroimmunol. Neuroinflamm. 4, e403.

Geyer M.B., Rivière I., Sénéchal B., Wang X., Wang Y., Purdon T.J., Hsu M., Devlin S.M., Palomba M.L., Halton E., Bernal Y., Sadelain M., Park J.H., Brentjens R.J.Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.. JCI Insight. 2019; 5. pii: 122627.

Giovannoni, G., 2017. Cladribine to treat relapsing forms of multiple sclerosis. Neurotherapeutics 14, 874–887.

Giovannoni, G., 2018. Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm. Curr. Opin. Neurol. 31, 233–243.

Giovannoni, G., Soelberg Sorensen, P., Cook, S., Rammohan, K., Rieckmann, P., Comi, G., Dangond, F., Adeniji, A.K., Vermersch, P., 2018. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult. Scler. 24, 1594–1604.

Gonsette, R., Debouverie, M., Sindic, C., Ferré, J.C., Edan, G., 2016. Pixantrone: a B-cell-depleting immunosuppressant for multiple sclerosis patients with active disease. Mult. Scler. 22, 817–821.

Grey Née Cotte, S., Salmen Née Stroet, A., von Ahsen, N., Starck, M., Winkelmann, A., Zettl, U.K., Comabella, M., Montalban, X., Zipp, F., Fleischer, V., Kruse, N., Gold, R., Chan, A., 2015. Lack of efficacy of mitoxantrone in primary progressive multiple sclerosis irrespective of pharmacogenetic factors: a multi-center, retrospective analysis. J. Neuroimmunol. 278, 277–279.

Gueneau, P., Chretien, M.L., Cransac-Miet, A., Aho, L.S., Lafon, I., Favennec, C., Guy, J., Caillot, D., Boulin, M., 2018 d d. Efficacy, safety, and cost of pomalidomide in relapsed and refractory multiple myeloma. Eur. J. Haematol. https://doi.org/10.1111/ejh.13039. Epub ahead of print].

Harigai, M., Tanaka, Y., Maisawa, S., JA21963 Study Group, 2012. Safety and efficacy of various dosages of ocrelizumab in Japanese patients with rheumatoid arthritis with an inadequate response to methotrexate therapy: a placebo-controlled double-blind parallel-group study. J. Rheumatol. 39, 486–495.

Hauser, S.L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H.P., Hemmer, B., Lublin, F., Montalban, X., Rammohan, K.W., Selmaj, K., Traboulsee, A., Wolinsky, J.S., Arnold, D.L., Klingelschmitt, G., Masterman, D., Fontoura, P., Belachew, S., Chin, P., Mairon, N., Garren, H., Kappos, L., OPERA I and OPERA II Clinical Investigators, 2017. Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis. N. Engl. J.

Med. 376, 221–234.

Hawker, K., O'Connor, P., Freedman, M.S., Calabresi, P.A., Antel, J., Simon, J., Hauser, S., Waubant, E., Vollmer, T., Panitch, H., Zhang, J., Chin, P., Smith, C.H., OLYMPUS trial group, 2009. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann. Neurol. 66, 460–471.

Housley, W.J., Pitt, D., Hafler, D.A., 2015. Biomarkers in multiple sclerosis. Clin. Immunol. 161, 51–58.

Ireland, S.J., Blazek, M., Harp, C.T., Greenberg, B., Frohman, E.M., Davis, L.S., Monson, N.L., 2012. Antibody-independent B cell effector functions in relapsing remitting multiple sclerosis: clues to increased inflammatory and reduced regulatory B cell capacity. Autoimmunity 45, 400–414.

Hsiehchen, D., Arasaratnam, R., Raj, K., Froehlich, T., Anderson, L., 2018. Ibrutinib use complicated by progressive multifocal leukoencephalopathy. Oncology 95, 319–322.

Jourdan M., Tarte K., Legouffe E., Brochier J., Rossi J.-F., Klein B.Tumor necrosis factor is a survival and proliferation factor for human myeloma cellsEur. Cytokine Netw.. 1999; 10: 65–70.

Karademir, B., Sari, G., Jannuzzi, A.T., Musunuri, S., Wicher, G., Grune, T., Mi, J., Hacioglu-Bay, H., Forsberg-Nilsson, K., Bergquist, J., Jung, T., 2018. Proteomic approach for understanding milder neurotoxicity of carfilzomib against bortezomib. Sci. Rep. 8, 16318.

Kappos, L., Li, D., Calabresi, P.A., O'Connor, P., Bar-Or, A., Barkhof, F., Yin, M., Leppert, D., Glanzman, R., Tinbergen, J., Hauser, S.L., 2011. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 378, 1779–1787.

Kappos, L., Hartung, Freedman, H.P., Boyko, M.S., Radü, A., Mikol, E.W., Lamarine, D.D., Hyvert, M., Freudensprung, Y., Plitz, U., van Beek, T., ATAMS Study Group, J., 2014. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Neurol. 13, 353–363.

Karnell, J.L., Karnell 3rd, F.G., Stephens, G.L., Rajan, B., Morehouse, C., Li, Y., Swerdlow, B., Wilson, M., Goldbach-Mansky, R., Groves, C., Coyle, A.J., Herbst, R., Ettinger, R., 2011. Mycophenolic acid differentially impacts B cell function depending on the stage of differentiation. J. Immunol. 187, 3603–3612.

Kearns, C.M., Blakley, R.L., Santana, V.M., Crom, W.R., 1994. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. Cancer Res. 54, 1235–1239.

Kemanetzoglou, E., Andreadou, E., 2017. CNS demyelination with TNF-α blockers. Curr. Neurol. Neurosci. Rep. 17, 36.

Kikuchi A., Kawada H., Iwaki Y., Machida S., Tsuchiya T., Fukuda R., Hotta T. Measurement of rituximab concentration in the cerebrospinal fluid in CNS lymphoma Rinsho Ketsueki. 2004; 45:1255–1257.

Komori, M., Lin, Y.C., Cortese, I., Blake, A., Ohayon, J., Cherup, J., Maric, D., Kosa, P., Wu, T., Bielekova, B., 2016. Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Ann. Clin. Transl. Neurol. 3, 166–179.

Klimatcheva, E., Pandina, T., Reilly, C., Torno, S., Bussler, H., Scrivens, M., Jonason, A., Mallow, C., Doherty, M., Paris, M., Smith, E.S., Zauderer, M., 2015. CXCL13 antibody for the treatment of autoimmune disorders. BMC Immunol. 16, 6.

Krishnan, C., Kaplin, A.I., Brodsky, R.A., Drachman, D.B., Jones, R.J., Pham, D.L., Richert, N.D., Pardo, C.A., Yousem, D.M., Hammond, E., Quigg, M., Trecker, C., McArthur, J.C., Nath, A., Greenberg, B.M., Calabresi, P.A., Kerr, D.A., 2008. Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch. Neurol. 65, 1044–1051.

La Mantia, L., Milanese, C., Mascoli, N., D'Amico, R., Weinstock-Guttman, B., 2007. Cyclophosphamide for multiple sclerosis. Cochrane Database Syst. Rev. 1 CD002819.

Lublin, F.D., 2014. New multiple sclerosis phenotypic classification. Eur. Neurol. 72 (Suppl 1), 1–5.

Macallan, D.C., Asquith, B., Irvine, A.J., Wallace, D.L., Worth, A., Ghattas, H., Zhang, Y., Griffin, G.E., Tough, D.F., 2003. Beverley PC measurement and modeling of human t cell kinetics. Eur. J. Immunol. 33, 2316–2326.

Macallan D.C., Wallace D.L. Zhang Y., Ghaftas H., Asquith B., de Lara C., Worth A., Panayiotakopoulos Griffn G.E., Tough D.F., Beverley P.C.L.B-cell kinetics in humans: rapid turnover of peripheral blood memory cells blood. 2005; 105: 3633–3640.

Mackay, F., Schneider, P., Rennery, P., 2003. Browning J BAFF and APRIL: a tutorial on B cell survival. Ann. Rev. Immunol. 21, 231–264.

Martinelli Boneschi, F., Vacchi, L., Rovaris, M., Capra, R., Comi, G., 2013. Mitoxantrone for multiple sclerosis. Cochrane Database Syst. Rev. 5, CD002127.

Michel, L., Vukusic, S., De Seze, J., Ducray, F., Ongagna, J.C., Lefrère, F., Jacq-Foucher, M., Confavreux, C., Wiertlewski, S., Laplaud, D.A., 2014. Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients. J. Neurol. Neurosurg. Psychiatry 85, 279–283.

Minagawa, H., Takenaka, A., Itoyama, Y., Mori, R., 1987. Experimental allergic encephalomyelitis in the Lewis rat. A model of predictable relapse by cyclophosphamide. J. Neurol. Sci. 78, 225–235.

Montalban, X., Hauser, S.L., Kappos, L., Arnold, D.L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H.P., Hemmer, B., Lublin, F., Rammohan, K.W., Selmaj, K., Traboulsee, A., Sauter, A., Masterman, D., Fontoura, P., Belachew, S., Garren, H., Mairon, N., Chin, P., Wolinsky, J.S., ORATORIO Clinical Investigators, 2017. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N. Engl. J. Med. 376, 209–220.

Montalban, X., Arnold, D.L., Weber, M.S., Staikov, I., Piasecka-Stryczynska, K., Wilmer, J., Martin, E.C., Dangond, F., Syed, S., Wolinsky, J.S., 2019. Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis. N. Engl. J. Med. 380, 2406–2417.

Mulder, A., Heidt, S., Vergunst, M., Roelen, D.L., Claas, F.H., 2013. Proteasome inhibition profoundly affects activated human B cells. Transplantation 95, 1331–1337.

Mulero, P., Midaglia, L., Montalban, X., 2018. Ocrelizumab: a new milestone in multiple sclerosis therapy. Ther. Adv. Neurol. Disord. 11, 1756286418773025.

Myers, L.W., Ellison, G.W., Merrill, J.E., El Hajjar, A., St Pierre, B., Hijazin, M., Leake, B.D., Bentson, J.R., Nuwer, M.R., Tourtellotte, W.W., Davis, P., Granger, D., Fahey, J.L., 1998. Pentoxifylline is not a promising treatment for multiple sclerosis in progression phase. Neurology 51, 1483–1486.

Nash, R.A., Bowen, J.D., McSweeney, P.A., Pavletic, S.Z., Maravilla, K.R., Park, M.S., Storek, J., Sullivan, K.M., Al-Omaishi, J., Corboy, J.R., DiPersio, J., Georges, G.E., Gooley, T.A., Holmberg, L.A., LeMaistre, C.F., Ryan, K., Openshaw, H., Sunderhaus, J., Storb, R., Zunt, J., Kraft, G.H., 2003. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 102, 2364–2372.

O'Neill, J.K., Baker, D., Davison, A.N., Maggon, K.K., Jaffee, B.D., Turk, J.L., 1992. Therapy of chronic relapsing experimental allergic encephalomyelitis and the role of the blood-brain barrier: elucidation by the action of brequinar sodium. J. Neuroimmunol. 38, 53–62.

Openshaw, H., Lund, B.T., Kashyap, A., Atkinson, R., Sniecinski, I., Weiner, L.P., Forman, S., 2000. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring. Biol. Blood Marrow Transplant. 6 (5A), 563–575.

Pal Singh, S., Dammeijer, F., Hendriks, R.W., 2018. Role of Bruton's tyrosine kinase in b cells and malignancies. Mol. Cancer 17, 57.

Paulino, L.R.F.M., Cunha, E.V., Barbalho Silva, A.W., Souza, G.B., Lopes, E.P.F., Donato, M.A.M., Peixoto, C.A., Matos-Brito, B.G., van den Hurk, R., Silva, J.R.V., 2018. Effects of tumour necrosis factor-alpha and interleukin-1 beta on in vitro development of bovine secondary follicles. Reprod. Domest. Anim. 53, 997–1005.

Pender, M.P., Burrows, S.R., 2014. Epstein–Barr virus and multiple sclerosis: potential opportunities for immunotherapy. Clin. Transl. Immunol. 3, e27.

Pender, M.P., Csurhes, P.A., Smith, C., Douglas, N.L., Neller, M.A., Beagley, L., Rehan, S., Hopkins, T.J., Thompson, K.M., Blum, S., Green, K.A., Ioannides, Z.A., Coulthard, A., Hooper, K.D., Burrows, S.R., Khanna, R., 2017. Safety and clinical improvement in a phase I trial of autologous Epstein–Barr virus-specific T cell therapy in patients with progressive multiple sclerosis. Mult. Scle. J. 23 (S3), 401.

Perales, M.A., Kebriaei, P., Kean, L.S., Sadelain, M., 2018. of: building a safer and faster car: seatbelts, airbags, and CRISPR. Biol. Blood Marrow Transplant. 24 (3S), S15–S19.

Pryce, G., Baker, D., 2018. Oligoclonal bands in multiple sclerosis; functional significance and therapeutic implications. Does the specificity matter? Mult. Scler. Relat. Disord. 25, 131–137.

Ramsköld, D., Parodis, I., Lakshmikanth, T., Sippl, N., Khademi, M., Chen, Y., Zickert, A., Mikeš, J., Achour, A., Amara, K., Piehl, F., Brodin, P., Gunnarsson, I., Malmström, V., 2019. B cell alterations during BAFF inhibition with belimumab in SLE. EBioMedicine 40, 517–527.

Rejdak, C., Stelmasiak, Z., Grieb, P., 2018. Cladribine induces long lasting oligoclonal bans disappearance in relapsing multiple sclerosis patients:10 year observational study. Mult. Scler. Rel. Disord. 27, 117–120.

Rice, G.P., Filippi, M., Comi, G., 2000. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurol. 54, 1145–1155.

Robak, P., Robak, T., 2016. Management of multiple myeloma with second-generation antibody-drug conjugates. BioDrugs 30, 87–93.

Robak, P., Robak, T., 2017. Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia. Expert Opin. Investig. Drugs 26, 1249–1265.

Ruella, M., June, C.H., 2016. Chimeric antigen receptor T cells for B cell neoplasms: choose the right CAR for you. Curr. Hematol. Malig. Rep. 11, 368–384.

Sabatinon, J.J., Zamvil, S.S., Hauser, S.L., 2019. B-cell therapies in multiple sclerosis. Cold Spring Harb. Perspect. Med. 9, a032037.

Saiz, A., Carreras, E., Berenguer, J., Yagüe, J., Martínez, C., Marín, P., Rovira, M., Pujol, T., Arbizu, T., Graus, F., 2001. MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS. Neurology 56, 1084–1089.

San Segundo, D., Ballesteros, M.A., Mons, R., San Martín, M., Zurbano, F., Miñambres, E., López-Hoyos, M., 2012. Study of B-cell subpopulations in lung transplant recipients with posttransplant infection. Transplant. Proc. 44, 2676–2678.

Schattling, B., Engler, J.B., Volkmann, C., Rothammer, N., Woo, M.S., Petersen, M., Winkler, I., Kaufmann, M., Rosenkranz, S.C., Fejtova, A., Thomas, U., Bose, A., Bauer, S., Träger, S., Miller, K.K., Brück, W., Duncan, K.E., Salinas, G., Soba, P., Gundelfinger, E.D., Merkler, D., Friese, M.A., 2019. Bassoon proteinopathy drives neurodegeneration in multiple sclerosis. Nat. Neurosci. 22, 887–896.

Schenkein D.Proteasome inhibitors in the treatment of B-cell malignancies.Clin. Lymphoma2002; 3:49–55.

Schönfeld, K., Zuber, C., Pinkas, J., Häder, T., Bernöster, K., Uherek, C., 2017. Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: preclinical studies. J. Hematol. Oncol. 10, 13.

Sefia, E., Pryce, G., Meier, U.C., Giovannoni, G., Baker, D., 2017. Depletion of CD20 B cells fails to inhibit relapsing mouse experimental autoimmune encephalomyelitis. Mult. Scler. Relat. Disord. 14, 46–50.

Sergott, R.C., Bennett, J.L., Rieckmann, P., Montalban, X., Mikol, D., Freudensprung, U., Plitz, T., van Beek, J., ATON Trial Group, 2015. ATON: results from a phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis. J. Neurol. Sci. 351, 174–178.

Silk, M., Nantz, E., 2018. Efficacy and safety of tabalumab in patients with relapsing-remitting multiple sclerosis: a Randomized, double-blind. Placebo-Controlled Study Neurol. 90 (15 Suppl), P3 397.

Sipe, J.C., Romine, J.S., Koziol, J.A., McMillan, R., Zyroff, J., Beutler, E., 1994. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 344, 9–13.

Sommer, N., Löschmann, P.A., Northoff, G.H., Weller, M., Steinbrecher, A., Steinbach, J.P., Lichtenfels, R., Meyermann, R., Riethmüller, A., Fontana, A., Dichgans, J., Martin, R., 1995. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat. Med. 1, 244–248.

Storek, J., Zhao, Z., Lin, E., Berger, T., McSweeney, P.A., Nash, R.A., Akatsuka, Y., Metcalf, M.D., Lu, H., Kalina, T., Reindl, M., Storb, R., Hansen, J.A., Sullivan, K.M., Kraft, G.H., Furst, D.E., Maloney, D.G., 2004. Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases). Clin. Immunol. 113, 285–298.

Studer, V., Rossi, S., Motta, C., Buttari, F., Centonze, D., 2014. Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive multiple sclerosis. J. Neuroimmunol. 276, 229–231.

Stüve, O., Cepok, S., Elias, B., Saleh, A., Hartung, H.P., Hemmer, B., Kieseier, B., 2005. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch. Neurol. 62, 1620–1623.

Tillman, B.F., Pauff, J.M., Satyanarayana, G., Talbott, M., Warner, J.L., 2018. Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies. Eur. J. Haematol. 100, 325–334.

Topping, J., Dobson, R., Lapin, S., Maslyanskiy, A., Kropshofer, H., Leppert, D., Giovannoni, G., Evdoshenko, E., 2016. The effects of intrathecal rituximab on biomarkers in multiple sclerosis. Mult. Scler. Relat. Disord. 6, 49–53.

Tran, J.Q., Rana, J., Barkhof, F., Melamed, I., Gevorkyan, H., Wattjes, M.P., de Jong, R., Brosofsky, K., Ray, S., Xu, L., Zhao, J., Parr, E., Cadavid, D., 2014. Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. Neurol. Neuroimmunol. Neuroinflamm. 1, e18.

van Hoppe, S., Rood, J.J.M., Buil, L., Wagenaar, E., Sparidans, R.W., Beijnen, J.H., Schinkel, A.H., 2018. P-Glycoprotein (MDR1/ABCB1) restricts brain penetration of the Bruton's tyrosine kinase inhibitor Ibrutinib, while cytochrome P450-3A (CYP3A) limits its oral bioavailability. Mol. Pharm. 15, 5124–5134.

Wu, J., Liu, C., Tsui, S.T., Liu, D., 2016. Second-generation inhibitors of Bruton tyrosine kinase. J. Hematol. Oncol. 9, 80.

Xiao, Y., Huang, J., Luo, H., Wang, J., 2014. Mycophenolate mofetil for relapsing-remitting multiple sclerosis. Cochrane Database Syst. Rev. 2, CD01024.

Zhang, W.Y., Wang, Y., Guo, Y.L., Dai, H.R., Yang, Q.M., Zhang, Y.J., Zhang, Y., Chen, M.X., Wang, C.M., Feng, K.C., Li, S.X., Liu, Y., Shi, F.X., Luo, C., Han, W.D., 2016. Treatment of CD20-directed chimeric antigen receptor-modified t cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report. Signal Transduct. Target Ther. 1, 16002.

Zhang, W.Y., Liu, Y., Wang, Y., Wang, C.M., Yang, Q.M., Zhu, H.L., Han, W.D., 2017. Long-term safety and efficacy of CART-20 cells in patients with refractory or relapsed B-cell non-Hodgkin lymphoma: 5-years follow-up results of the phase I and IIa trials. Signal Transduct. Target Ther. 2, 17054.

Zhao, L., Jiang, Z., Jiang, Y., Ma, N., Wang, K., Zhang, Y., 2012. Changes in immune cell frequencies after cyclophosphamide or mycophenolate mofetil treatments in patients with systemic lupus erythematosus. Clin. Rheumatol. 31, 951–959.